Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 17/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | PLK1 | P53350 | 3/20 | 1.00 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 2/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 2/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | PRKX | P51817 | 2/20 | 1.00 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 1.00 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 1.00 |
| ▸ | CSNK1G3 | Q9Y6M4 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4368075 | 1.00 | MAPKAPK2 (1.00) | MAPKAPK2ROCK1AURKBPLK1CSNK1G1 | |
| SCHEMBL4364169 | 1.00 | MAPKAPK2 (1.00) | MAPKAPK2ROCK1AURKBPLK1CSNK1G1 | |
| SCHEMBL4376007 | 0.92 | MAPKAPK2 (0.86) | MAPKAPK2ROCK1AURKBPLK1CSNK1G1 | |
| SCHEMBL4378173 | 0.92 | MAPKAPK2 (0.85) | MAPKAPK2ROCK1AURKBPLK1CSNK1G1 | |
| SCHEMBL17920542 | 0.89 | MAPKAPK2 (0.80) | MAPKAPK2ROCK1AURKBPLK1CSNK1G1 | |
| SCHEMBL4371766 | 0.89 | MAPKAPK2 (0.91) | MAPKAPK2ROCK1AURKBPLK1CSNK1G1 | |
| SCHEMBL4366807 | 0.88 | MAPKAPK2 (0.79) | MAPKAPK2ROCK1AURKBPLK1CSNK1G1 | |
| SCHEMBL4368077 | 0.87 | MAPKAPK2 (0.78) | MAPKAPK2ROCK1AURKBPLK1CSNK1G1 | |
| SCHEMBL4365525 | 0.86 | MAPKAPK2 (0.76) | MAPKAPK2ROCK1AURKBPLK1CSNK1G1 | |
| SCHEMBL4364001 | 0.86 | MAPKAPK2 (1.00) | MAPKAPK2ROCK1AURKBPLK1CSNK1G1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459570-B2 | Transgenic mouse expressing amyloid precursor protein that has olfactory neuron degeneration | THE GENERAL HOSPITAL CORPORATION (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20200308240-A1 | Targeting Innate Immune Signaling in Neuroinflammation and Neurodegeneration | THE GENERAL HOSPITAL CORPORATION | 2020-10-01 | — | — | US | disclosed |
| US-20190352643-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION | 2019-11-21 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190134153-A1 | IMMUNOMODULATORY EFFECT OF INHALED KINASE INHIBITOR PEPTIDES IN LUNG | MOERAE MATRIX, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190031730-A1 | FORMULATION OF MK2 INHIBITOR PEPTIDES | MOERAE MATRIX, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190022176-A1 | USE OF MK2 INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME | MOERAE MATRIX, INC. | 2019-01-24 | — | — | US | disclosed |
| US-9999655-B2 | Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | MOERAE MATRIX, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9999655-B2 | Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | MOERAE MATRIX, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170335324-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH | 2017-11-23 | — | — | US | disclosed |
| US-20160263187-A1 | USE OF MKS INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME | MOERAE MATRIX, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160263187-A1 | USE OF MKS INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME | MOERAE MATRIX, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160200782-A1 | FORMULATION OF MK2 INHIBITOR PEPTIDES | MOERAE MATRIX, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160200782-A1 | FORMULATION OF MK2 INHIBITOR PEPTIDES | MOERAE MATRIX, INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2016077595-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2009012375-A2 | SQUARATE KINASE INHIBITORS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
| US-5605909-A | REDUCING ADVERSE EFFECTS OF SMOOTH MUSCLE CONTRACTIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| US-5532245-A | TO REDUCE SMOOTH MUSCLE CONTRACTIONS; TREATMENT FOR URINARY INCONTINENCE, IRITABLE BOWEL SYNDROME | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-02 | — | — | US | disclosed |
| US-5466712-A | Smooth muscle relaxants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335324-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, APP | MAPKAPK2 2047/4885ROCK1 4350/4885AURKB 4436/4885 |
| US-11459570-B2 | Transgenic mouse expressing amyloid precursor protein that has olfactory neuron degeneration | APP, PSEN1, PSEN2 | MAPKAPK2 2726/4885ROCK1 4475/4885AURKB 4730/4885 |
| US-20160200782-A1 | FORMULATION OF MK2 INHIBITOR PEPTIDES | MKNK2, NPY2R, PPP2R2A | MAPKAPK2 14/4885ROCK1 837/4885AURKB 250/4885 |
| US-20190352643-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | PSEN2, NLN, HTT | MAPKAPK2 1542/4885ROCK1 522/4885AURKB 3427/4885 |
| US-20200308240-A1 | Targeting Innate Immune Signaling in Neuroinflammation and Neurodegeneration | TBK1, STAT1, IRF3 | MAPKAPK2 84/4885ROCK1 349/4885AURKB 875/4885 |
| US-20190022176-A1 | USE OF MK2 INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME | MKNK2, KSR2, MKNK1 | MAPKAPK2 13/4885ROCK1 736/4885AURKB 182/4885 |
| US-20190134153-A1 | IMMUNOMODULATORY EFFECT OF INHALED KINASE INHIBITOR PEPTIDES IN LUNG | IRAK1, IRAK2, IRAK4 | MAPKAPK2 36/4885ROCK1 562/4885AURKB 435/4885 |
| US-20190031730-A1 | FORMULATION OF MK2 INHIBITOR PEPTIDES | MKNK2, NPY2R, PPP2R2A | MAPKAPK2 14/4885ROCK1 837/4885AURKB 250/4885 |
| US-20160263187-A1 | USE OF MKS INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME | SRMS, MKNK1, MKNK2 | MAPKAPK2 171/4885ROCK1 469/4885AURKB 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.